In a regulatory filing, Scilex Holding stated that on June 17, the board of directors of the company approved a resolution to authorize management to explore ways in which to maximize the value of Semnur Pharmaceuticals, the company’s wholly owned subsidiary, and SP-102, or SEMDEXA, the product candidate held by Semnur, for the company and its stockholders, including by way of conducting a spin-off, merger, dividend, reclassification or other similar transaction.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCLX:
- Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
- Scilex to present poster on ELYXYB at AHS meeting
- Scilex Holding Company to Present Poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024
- Scilex initiated with a Buy at Rodman & Renshaw
- Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies